Scaling of cardiac electrophysiology with body mass requires large changes in the ventricular action potential duration and heart rate in mammals. These changes in cellular electrophysiological function are produced by systematic and coordinated changes in the expression of multiple ion channel and transporter genes. Expression of one important potassium current, the transient outward current (I to ), changes significantly during mammalian evolution. Changes in I to expression are determined, in part, by variation in the expression of an obligatory auxiliary subunit encoded by the KChIP2 gene. The KChIP2 gene is expressed in both cardiac myocytes and neurons and transcription in both cell types is initiated from the same CpG island promoter. Species-dependent variation of KChIP2 expression in heart is mediated by the evolution of the cis-regulatory function of this gene. Surprisingly, the major locus of evolutionary change for KChIP2 gene expression in heart lies within the CpG island core promoter. The results demonstrate that CpG island promoters are not simply permissive for gene expression but can also contribute to tissue-selective expression and, as such, can function as an important locus for the evolution of cisregulatory function. More generally, evolution of the cis-regulatory function of voltage-gated ion channel genes appears to be an effective and efficient way to modify channel expression levels to optimize electrophysiological function.
cis-regulatory evolution | physiological scaling L arge differences in body mass among mammals require significant changes in heart rate and ventricular action potential duration to scale cardiac physiological function to body mass (1, 2) . These changes in cardiac function are produced by systematic changes in myocyte electrophysiological function and in the pattern and level of expression of multiple voltage-gated ion channels and transporters (2) . Some of the most prominent changes are seen in the changing role of the transient outward potassium current (I to ). The I to current is a rapidly activating and inactivating current that is expressed in the ventricular myocytes of most, but not all, mammalian hearts (3) . Expression of this current in heart appears to be an innovation of mammals. This current has not been described in the hearts of nonmammalian vertebrates. An essentially identical current (known as I A ) is, however, expressed in the brains of most vertebrate and many invertebrate species (4) . A subset of the genes that encode the neuronal I A current in mammals has been coopted for I to expression in heart (2, 3) .
The ventricular action potential in most nonrodent mammals has a "spike and dome" morphology, with a long plateau phase before action potential repolarization. In these species, I to modifies the early phase of action potential morphology, altering the initial rate of calcium ion entry and the strength of myocyte contraction (5) . The I to channel is composed of an α-subunit encoded by the Kv4.3 gene (KCND3) and an auxiliary subunit encoded by the KChIP2 gene (KCNIP2) in these species (3) . Differences in I to and KChIP2 expression within the ventricles (6, 7) contribute to regional differences in ventricular contractility and coordination of ventricular contraction (5). The broad phylogenetic distribution of this particular pattern of I to gene expression (3) suggests that it was established early in mammalian evolution.
I to and KChIP2 expression vary significantly from the common mammalian pattern in some rodents. In guinea pig, I to expression (8) and KChIP2 expression have been lost, although the action potential is similar in most other respects to other nonrodent mammals. In contrast, mouse and closely related species express I to at very high levels. In these species the ventricular action potential is very short with a triangular waveform (2, 3, 9) , due to the large size and rapid activation of the I to current. The short action potential duration and altered morphology contribute to the scaling of ventricular action potential duration (2) . In mouse and related species, I to is encoded by both Kv4.3 and a second α-subunit gene Kv4.2, which is only expressed in the hearts of this subset of rodents (2) . Cardiac Kv4.2 gene expression is produced by evolutionarily mediated changes in the cis-regulatory function of the Kv4.2 gene in these species (2) . There is a complementary increase in KChIP2 gene expression in these species that also contributes to increased I to expression.
Despite complex biosynthetic pathways, voltage gated ion channel expression in heart is primarily determined by the level of channel gene transcription (10, 11) . The size of the I to current is directly dependent upon the level of KChIP2 gene expression (7, 12) . The large changes in KChIP2 gene expression in mammalian heart and compact gene structure make it a favorable model in which to study the contribution of cis-regulatory evolution to the evolution of physiological function in mammals. The results presented in this paper demonstrate that the KChIP2 gene contains a CpG island promoter that is not simply permissive for gene transcription but also contributes significantly to the tissue specificity of gene expression and is a primary locus for the evolution of KChIP2 gene expression patterns in mammalian heart.
Results
Expression of the KChIP2 Gene in Cardiac Ventricle. KChIP2 mRNA expression in the left ventricular wall of hearts from six different species was determined (Fig. 1A) . KChIP2 mRNA was expressed at moderate levels in nonrodent mammals. Expression was high in mouse and rat, consistent with the high level of I to expression in these species (2, 3). There was an almost complete absence of KChIP2 expression in the guinea pig ventricle, concordant with the lack of I to expression in this species (8) .
KChIP2 gene regulatory function was initially analyzed in three species: mouse, representative of small rodents that have a large I to ; guinea pig, a rodent that lacks significant KChIP2 and I to expression; and human, representative of the majority of mammals that have a relatively small but functionally important I to .
KChIP2 Transcription Start Site Mapping. The transcription start site (TSS) for the KChIP2 gene was mapped in mouse and human heart and brain and guinea pig brain (Fig. 1B) . Mapping of the TSS in guinea pig heart was not attempted due to the very low level of transcripts in this tissue. In the mouse, transcription was initiated primarily at a single primary transcription start site. The human and guinea pig transcription start sites were more dispersed. Multiple transcription start sites were found in these species, although they were restricted to a relatively small region. Notably, for both mouse and human, the same transcription start sites are used in heart and brain, indicating that the same promoter is used in both tissues.
The sequence around the transcription start site of the three species is generally well conserved, although it contains some small deletions (Fig. 1C) . The transcription start sites for all three species are located within a CpG island (Fig. 1D ) and the promoter region in all three species has the typical properties of a CpG island promoter (13) . In particular, this region lacks a consensus TATA box or TFIIB Recognition element, Initiator element, and Downstream Promoter element with the expected relationship to the transcription start site (14) . The highly focused nature of the mouse TSS is relatively unusual for this class of promoters, with the human and guinea pig TSS patterns being more typical (13) .
Comparison of KChIP2 Proximal Promoter Function and mRNA
Expression. The KChIP2 gene is located within a gene-rich region of chromosomes 19 and 10 in mouse and human, respectively. The gene is closely bounded in the 5′ direction by another transcription unit (C10orf76), resulting in a relatively compact upstream regulatory region. Equivalent, ∼2.5 kb, 5′-intergenic regions containing the core promoter were selected from mouse, guinea pig, and human genomic sequences and then tested using an in vitro transcription assay in cultured rat myocytes. There was a good correspondence between the function of this region and the relative level of mRNA expression in cardiac ventricles from the corresponding species ( Fig. 2 A and B) , suggesting that this region was likely to make a primary contribution to the species differences in KChIP2 transcriptional function in heart.
The presence of 5′-UTR sequence in the constructs raised the possibility that some of the differences in reporter gene expression between the different species could be due to differences in the translational efficiency of the transcribed mRNAs. To test this possibility, transcription from the reporter genes was measured directly using real-time PCR (Fig. 2C) . The species differences in transcriptional activity were maintained when assessed directly from mRNA levels. Mapping of the KChIP2 transcription start sites using mouse and human heart and brain mRNA and guinea pig brain mRNA. The y axis indicates the number of RACE PCR clones that were sequenced and mapped to the respective nucleotide position indicated on the x axis. (C) Alignment of mouse, human, and guinea pig sequences encompassing the transcription start sites shown in B. Numbering of the x axis is relative to the primary transcription start site (+1) in mouse and guinea pig and the second most common start site in human. The primary TSS in human is marked with an "H." (D) Analysis of CpG frequency around the KChIP2 transcription start site of the mouse, human, and guinea pig genes. The standard threshold for CpG island prediction (observed CpG / expected CpG > 0.65) (33) is marked with a dashed red line. The lower CpG frequency in the mouse KChIP2 gene and the loss of apparently nonfunctional CpG islands is reflective of genome-wide trends in this species (34) . The transcription start site was aligned for all three species and is marked by an arrow. The exons are marked by gray bars. At the most commonly used TSS in each species, the [−1,+1] dinucleotide was C:A, a pyrimidine:purine pair, which conforms to the consensus at this location (13) . In the human the second most commonly used site, equivalent to the primary site in mouse and guinea pig, was also a pyrimidine:purine pair, although in this case a C:G pair. The plots use a 200-bp window to calculate obs CpG /exp CpG .
The transcription activity assays were performed using cultured rat myocytes. The use of this culture system assumes that the evolution of KChIP2 cis-regulatory function is fast relative to any potential evolutionarily mediated changes in transcription factor network function. This assumption is consistent with the fact that, with the exception of cellular electrophysiology, myocyte morphology and function are generally very well conserved in mammals (2) . The observation that mouse, guinea pig, and human KChIP2 promoter activity matches relative mRNA abundance rather than the degree of phylogenetic relatedness to the cell culture system also supports this assumption ( Fig. 2  A and B) .
We directly tested the effect of cell species using cultured ferret embryonic ventricular myocytes. Ferret is an out-group relative to Euarchontoglires (the superclade containing mouse, guinea pig, and human) and both KChIP2 mRNA (Fig. 1A ) and I to (15) are expressed in ferret heart at similar levels to that seen in human. The differences in mouse, guinea pig, and human KChIP2 transcriptional activity are retained in the ferret cultures (Fig. 2D ) and are independent of both the species (ferret versus rat) and developmental stage (embryonic versus neonatal) of the culture system. This observation supports our general hypothesis that cis-regulatory function is the primary mechanism responsible for changes in ion channel expression in heart and that transcription factor function and expression remain relatively invariant in mammalian heart (2).
KChIP2 Proximal Promoter Function. An alignment of the proximal promoter region from mouse, human, and guinea pig shows that regions upstream of the CpG island are relatively poorly conserved (Fig. 3A) . The conserved regions at the 5′ end of this sequence are associated with the upstream genes' transcription unit.
To isolate the regions responsible for the species differences in promoter function, a series of 5′ deletions were performed (Fig.  3B) . Increasingly large deletions had relatively little effect on both the absolute level of activity (Fig. 3C) and the relative level of activity (Fig. 3D ) of promoter function for the three species.
Notably, even the shortest sequence, which encompasses the CpG island containing only the core promoter and 5′-UTR, retained most of the difference in expression between mouse, human, and guinea pig genes ( Fig. 3 C and D) , suggesting that the primary differences between the species are located within the CpG island.
Substitution of the CpG Island Between Mouse and Guinea Pig. To further confirm that the CpG island region plays the predominant role in determining the species differences in promoter function, this region was swapped between the mouse and guinea pig proximal regulatory regions (Fig. 4A) . Substituting the guinea pig sequence into the mouse background produced a more than fourfold reduction in expression relative to the mouse sequence (Fig. 4B) . The converse experiment produced a more than eightfold increase in expression relative to the guinea pig sequence.
The upstream 5′ regulatory region clearly modifies the activity of the CpG island to some extent, as seen by comparison of mouse to the guinea pig-mouse hybrid and guinea pig to the mouse-guinea pig hybrid (Fig. 4 A and B) . Nonetheless, it is clear that the CpG island is the major determinant of the species differences in KChIP2 promoter function.
Localization of Sequence Changes Within the CpG Island Responsible
for Changes in Functional Activity. A series of swaps between the mouse and guinea pig CpG island were performed to localize the sequences responsible for the differences in transcriptional activity. This region was divided into four domains (Fig. 4C) : regions "a" and "b" correspond to roughly equal halves of the core promoter, with "b" containing the transcription start site. Region "c" corresponds to a poorly conserved region of the 5′-UTR that is largely deleted in guinea pig and "d" corresponds to a well-conserved region of the 5′-UTR that contains a conserved inverted repeat. Transcription assays showed that region "d" did not contribute to the functional differences (Fig. 4 C and D) . The other three regions contributed approximately equally. Considerable effort was expended to localize specific nucleotide changes responsible for these differences. Individual sequence changes had very modest effects on function, suggesting that the concerted effect of multiple changes is required to produce these differences in regulatory activity, as has been found in other systems (16) . Expression of KChIP2 varies most markedly in rodents. The function of the CpG island promoter from eight rodents and three nonrodents was compared (Fig. 5A) . High KChIP2 promoter function appears to be phylogenetically restricted to mouse and closely related species. Most rodents have intermediate function, similar to the level seen in nonrodents. Very low KChIP2 promoter function was restricted to guinea pig and chipmunk (Tamias striatus).
KChIP2 Proximal Promoter Function in Neurons. Mouse, guinea pig, and human KChIP2 proximal promoter function was tested in cultured rat cortical neurons. Mouse and human promoter function was indistinguishable in neurons (Fig. 5B) . Guinea pig promoter activity in neurons was reduced to ∼37% of the mouse and human levels. This level was significantly higher than that seen in myocytes ( Fig. 2A) but remains lower than mouse and human. There are no established species differences in I A function in mammalian neurons and it is unlikely that KChIP2 expression in equivalent neurons varies significantly between these species.
The reduction in guinea pig KChIP2 promoter activity in neurons suggests that changes in a neuron-specific enhancer element may be required to compensate for the weaker promoter function in neurons. Such an element was not identified in functional tests using the large first intron.
Discussion
The results reported here support the hypothesis that the large differences in the level of KChIP2 expression in mammalian heart are primarily due to evolutionarily mediated changes in the cis-regulatory function of the gene. This is demonstrated by the close match between KChIP2 mRNA expression and promoter function for different species and by the independence of the relative promoter function from the phylogenetic origin of the cultured cells in which functional promoter tests were performed.
Expression of the KChIP2 gene is primarily restricted to electrically excitable cells and this gene is expressed in both cardiac myocytes and a subset of neurons (17) (18) (19) . Transcription in both brain and heart tissues is initiated from the same CpG island promoter. Surprisingly, a major locus of evolutionary change for KChIP2 gene expression in heart lies within this CpG island core promoter. The species differences in KChIP2 mRNA expression in heart were matched by similar differences in the functional activity of this relatively small CpG island promoter from the same species.
Prior studies on the evolution of cis-regulatory function have generally found that evolutionarily mediated changes in gene regulatory function were localized to tissue-specific enhancer/ repressor elements separate from the core promoter (16, 20, 21) . Evolution of these tissue-restrictive elements is considered an effective way to modify regulatory function in a tissue-specific way, thereby limiting the pleiotropic effects of changes in gene regulatory function (22) . Evolution of KChIP2 regulatory function deviates from this pattern in that a major locus of change is the CpG island promoter itself.
The changes in regulatory function of the KChIP2 core promoter in cardiac tissue are, to some degree, tissue specific. For example, there are relatively large differences in mouse and human KChIP2 core promoter function in heart with essentially no difference in neuronal function. There are, however, limits to the tissue specificity of these changes. In the more extreme case of guinea pig, where KChIP2 expression in cardiac myocytes is largely eliminated, there was a significant reduction in neuronal function, although this was not as extreme as the reduction seen in myocytes. It is possible that compensatory changes may occur in other regulatory regions of the guinea pig gene, although these were not identified. The results suggest that tissue-selective changes in CpG island core promoter function are possible, although there are limitations in isolating the effect of these changes.
Approximately half of the tissue-restricted genes in mammals have CpG island promoters (23) and the KChIP2 gene is an apparently typical example of this class of genes. Results for the KChIP2 gene suggest that, at least for some of these tissuespecific genes, the CpG island promoter is not merely permissive for gene expression but can be a significant contributor to tissueselective expression. As such, for this class of promoters, the core promoter may itself be an important locus for evolutionarily mediated changes in tissue-selective regulatory function.
There is significant variation in the physiological function of the I to current in different rodent hearts. In mouse and closely related species, the I to current acquires a new function, becoming the major current underlying action potential repolarization (2, 9) . The large I to current produces a ventricular action potential of very short duration that matches the very fast heart rates in these species (2) . Enhanced KChIP2 gene regulatory function makes an essential contribution to the required changes in cardiac electrophysiological function in these species. For guinea pig (Cavia), and possibly Tamias, the ventricular action potential retains the classic spike and dome morphology seen in most mammals, albeit without the initial rapid phase 1 repolarization contributed by the I to current. The degenerative loss of I to current expression in guinea pig heart may reflect reduced importance of I to for coordinating contractile function in these relatively small hearts or the reduced requirement for the spare repolarization capacity provided by the I to in hearts that already have relatively large repolarizing I Ks and I Kr currents.
Expression of most voltage-gated ion channels in heart is transcriptionally regulated (10, 11) . A general property of excitable cells is that they are computational systems, in the sense that the output of the system is determined by the sum of the various currents that are expressed in the cell (24) . As a consequence, relatively modest quantitative changes in voltage-gated ion channel expression and channel gene cis-regulatory function can have large effects on cellular electrophysiological function. The evolution of KChIP2 cis-regulatory function within the rodent clade is an example of how ion channel gene cis-regulatory function can evolve over relatively short phylogenetic distances in a quantitative fashion to significantly alter electrophysiological function. Evolution of cis-regulatory function is a flexible and efficient way to modify cellular electrophysiological function and would seem to be the most reliable way to match channel expression levels to optimal electrophysiological function. It has been suggested that relatively complex cellular homeostatic mechanisms could be used to match voltage-gated ion channel expression levels to the required cellular electrophysiological function (25) . A simpler alternative is that the cis-regulatory function of ion channel genes can evolve over time to achieve this matching, in much the same way that the evolution of cisregulatory function establishes a wide range of phenotypic properties in most other cell types (26, 27) . This is not to say that there is not some environment-specific tuning of voltage-gated ion channel gene expression levels within individual cells, but it seems most likely that cis-regulatory evolution is the primary mechanism used to achieve appropriate channel expression levels in electrically excitable cells (24) .
Materials and Methods
All animal procedures have been approved by the institutional animal care and use committee of Stony Brook University.
Analysis of KChIP2 and Luciferase mRNA Expression. Analysis of mRNA expression in left ventricle wall was performed using real-time PCR as described previously (2, 28) . Animals were killed and the hearts were quickly removed before further dissection. Human RNA samples were obtained from two independent commercial suppliers (Ambion and BioChain). For luciferase mRNA quantitation, rat neonatal myocytes were isolated, transfected, and cultured for 48 h, as described below. After culture, cells were lysed by adding RLT buffer and passing the lysate over a Qiashredder column (Qiagen). Total RNA was prepared from tissues and cells using Qiagen RNeasy columns with DNase treatment. RNA samples were quantitated, rediluted to give nominally equal concentrations, and quantitated a second time using spectrophotometric analysis. cDNAs were prepared from a starting RNA amount of 5 μg per sample. In vitro reverse transcription was performed using SuperScript III reverse transcriptase (Invitrogen), as described previously (29) . Real-time PCR was performed using the SYBR Green QuantiTect PCR kit (Qiagen) with a 7300 Real-time PCR system (Applied Biosystems). Experimental samples were analyzed in triplicate. Threshold crossing points were converted to expression values automatically (30) . Real-time PCR products were analyzed by gel electrophoresis and sequenced to confirm specificity of the amplification. Gene expression across RNA samples was normalized using 18S and 28S rRNAs as internal controls.
Multiple (typically three) primer pairs were used to analyze expression to detect primer-dependent artifacts (2). The results from each primer pair were averaged. Primer sequences used for real-time PCR are listed in Table S1 .
BAC Library Screening. BAC clones encompassing the KChIP2 proximal promoter regions of guinea pig and hamster were identified in BAC libraries (BACPAC Resources Center) using a nonradioactive probe labeled with Digoxigenin-11-dUTP (DIG-11-dUTP alkali-labile; Roche). Probe sequences were based on cDNA sequences or conserved regions from multiple species. A 40-bp double-stranded DNA probe was synthesized using two 24-mer oligonucleotides with overlapping 3′ ends (5′ GGAGCCGTCGAGATCTCGAGA-GTC 3′ and 5′ TAAGGAGAGTTTGTCCGACTCTCG 3′), using Klenow fragment DNA Polymerase and a mixture of dNTPs and DIG-dUTP. Hybridization was carried out using buffers optimized for DIG labeled probe (DIG Easy Hyb; Roche). Signals were developed using immunological detection method with anti-DIG-AP, Fab fragments (Roche) and CDP-Star (Roche). Positive BAC clones identified from the screening were then obtained from the BACPAC Resources Center. The BAC clones were analyzed by fingerprinting, end sequencing, and finally sequencing of the specific region of interest.
Isolation, subcloning, and sequencing of genomic DNA regions were performed using standard techniques (as described in SI Materials and Methods).
TSS Mapping by RNA Ligase-Mediated RACE PCR. The transcription start site of the KChIP2 gene was mapped in mouse, guinea pig, and human with the RNA Ligase-Mediated RACE PCR technique (31) using the Ambion First Choice RLM-RACE kit (Applied Biosystems). Guinea pig brain and mouse brain and heart RNA were prepared as described previously (2) . Human brain and heart RNA were obtained from commercial suppliers (BioChain and Ambion, respectively).
Briefly, 10 μg of total RNA were ethanol precipitated and treated with calf intestine alkaline phosphatase (CIP) to remove the terminal 5′ phosphate group from degraded and uncapped RNAs. The samples were purified by phenol/chloroform and chloroform extraction, precipitated with isopropanol, and finally treated with tobacco acid pyrophosphatase (TAP) to remove the mRNA cap structure. An aliquot of the RNA sample was not treated with TAP and kept as a negative ("TAP-minus") control. An adapter was then ligated to the 5′ end of the RNA molecules using T4 single-strand RNA ligase. The previous CIP treatment step prevents adapter ligation to degraded/uncapped RNA molecules and ligation to capped RNAs cannot occur without removal of the cap structure. The ligated RNA was reverse transcribed at 50°C using Moloney murine leukemia virus reverse transcriptase and gene-specific primers (Table S2 ). The cDNAs obtained were then subjected to a first round of nested PCR (primers listed in Table S3 ). A second round of PCR (inner PCR) was performed by using 2 μL of the first PCR as template, and 3′ primers (Table S4 ). The inner PCR reactions were purified using the Qiaquick PCR Purification kit (Qiagen), subcloned into pBluescript SK, and sequenced.
Neonatal Myocyte Transfection, Culture, and Luciferase Assay. Rat cardiac myocytes were isolated from P2-P3 animals and cultured as described previously (32) . Ferret cardiac ventricular myocytes were isolated from E34 animals using the same procedure and then handled similarly to the rat myocytes. Cell transfection was performed using the Rat Cardiomyocyte Nucleofector kit (Lonza) in a Nucleofector I device (Lonza). Each sample included an internal control Renilla luciferase plasmid (phRL-SV40). Experiments always included a negative control sample (pGL2-basic), and a positive control (pGL2-control) when appropriate. After electroporation, the myocytes were plated onto fibronectin-gelatin-coated 12-well plates and cultured at 37°C in 5% CO 2 for 48 h. Firefly and Renilla luciferase activities were measured using the Dual Luciferase Reporter Assay kit (Promega) in a Lumat luminometer (Berthold). Mouse: 5′ AGGATAGGGCGCTCACACA 3′, 5′TCAGGGCTTTTTTACTGGGC 3′ Guinea pig: 5′ GGACAAGGCGCTTGCTCAAAC 3′, 5′TCAGCGCTTTTTTAGTGGGC 3′ Human: 5′ GCGCTCGAGTACTGTGCTGTCGGGGCT 3′, 5′GCGCTCGAGAAACTCTCCTTGCGGCCCTG 3′ Table S4 . Second round nested PCR primers
Mouse: 5′ GCGGAATTCAGCGACCTGCTGGGGCT 3′, 5′GCGGAATTCATAGGAGCCGTCCAAATCTC 3′ Guinea pig: 5′ GCGGAATTCTGAAGAGCCGAGGGGTCGT 3′, 5′ GCGGAATTCCGTAGGAGCCGTCGAGATCTC 3′ Human: 5′ GCGCTCGAGTACTGTGCTGTCGGGGCT 3′, 5′GCGCTCGAGAAACTCTCCTTGCGGCCCTG 3′
